MwanzoBNTX • NASDAQ
add
BioNTech SE
$Â 108.49
Baada ya Saa za Kazi:(0.049%)+0.053
$Â 108.54
Imefungwa: 6 Jun, 18:29:40 GMT -4 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$Â 110.15
Bei za siku
$Â 108.41 - $Â 110.72
Bei za mwaka
$Â 76.53 - $Â 131.49
Thamani ya kampuni katika soko
26.03B USD
Wastani wa hisa zilizouzwa
1.40M
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (EUR) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 182.80M | -2.56% |
Matumizi ya uendeshaji wa biashara | 593.40M | -6.05% |
Mapato halisi | -415.80M | -31.96% |
Kiwango cha faida halisi | -227.46 | -35.43% |
Mapato kwa kila hisa | -1.73 | -32.06% |
EBITDA | -451.60M | 2.84% |
Asilimia ya kodi ya mapato | 6.65% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (EUR) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 14.11B | -9.94% |
Jumla ya mali | 21.18B | -4.83% |
Jumla ya dhima | 2.26B | -1.43% |
Jumla ya hisa | 18.93B | — |
hisa zilizosalia | 240.39M | — |
Uwiano wa bei na thamani | 1.40 | — |
Faida inayotokana na mali | -5.65% | — |
Faida inayotokana mtaji | -6.36% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (EUR) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -415.80M | -31.96% |
Pesa kutokana na shughuli | -780.70M | -146.04% |
Pesa kutokana na uwekezaji | 1.25B | 154.11% |
Pesa kutokana na ufadhili | -13.80M | -76.92% |
Mabadiliko halisi ya pesa taslimu | 423.00M | 115.74% |
Mtiririko huru wa pesa | -1.37B | -175.36% |
Kuhusu
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2008
Tovuti
Wafanyakazi
6,772
